These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 34823541)

  • 1. Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy.
    Cai T; Liu H; Zhang S; Hu J; Zhang L
    J Nanobiotechnology; 2021 Nov; 19(1):389. PubMed ID: 34823541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-adjuvanting cancer nanovaccines.
    Liao Z; Huang J; Lo PC; Lovell JF; Jin H; Yang K
    J Nanobiotechnology; 2022 Jul; 20(1):345. PubMed ID: 35883176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanovaccines: An effective therapeutic approach for cancer therapy.
    Gurunathan S; Thangaraj P; Wang L; Cao Q; Kim JH
    Biomed Pharmacother; 2024 Jan; 170():115992. PubMed ID: 38070247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanovaccines for cancer immunotherapy.
    Zhang Y; Lin S; Wang XY; Zhu G
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Sep; 11(5):e1559. PubMed ID: 31172659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen.
    Hashemi Goradel N; Nemati M; Bakhshandeh A; Arashkia A; Negahdari B
    Int Immunopharmacol; 2023 Apr; 117():109887. PubMed ID: 36841155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses.
    Liu X; Feng Z; Wang C; Su Q; Song H; Zhang C; Huang P; Liang XJ; Dong A; Kong D; Wang W
    Biomaterials; 2020 Feb; 230():119649. PubMed ID: 31791843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient Nanovaccine Delivery in Cancer Immunotherapy.
    Zhu G; Zhang F; Ni Q; Niu G; Chen X
    ACS Nano; 2017 Mar; 11(3):2387-2392. PubMed ID: 28277646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanovaccines with cell-derived components for cancer immunotherapy.
    Meng Z; Zhang Y; Zhou X; Ji J; Liu Z
    Adv Drug Deliv Rev; 2022 Mar; 182():114107. PubMed ID: 34995678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrasound-Mediated Remotely Controlled Nanovaccine Delivery for Tumor Vaccination and Individualized Cancer Immunotherapy.
    Meng Z; Zhang Y; She J; Zhou X; Xu J; Han X; Wang C; Zhu M; Liu Z
    Nano Lett; 2021 Feb; 21(3):1228-1237. PubMed ID: 33522825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging advances in cationic liposomal cancer nanovaccines: opportunities and challenges.
    Ahmad MZ; Ahmad J; Alasmary MY; Abdel-Wahab BA; Warsi MH; Haque A; Chaubey P
    Immunotherapy; 2021 Apr; 13(6):491-507. PubMed ID: 33626936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy.
    Zhou S; Huang Y; Chen Y; Liu S; Xu M; Jiang T; Song Q; Jiang G; Gu X; Gao X; Chen J
    Biomaterials; 2020 Mar; 235():119795. PubMed ID: 32014739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging advances in synthetic cancer nano-vaccines: opportunities and challenges.
    Ahmad MZ; Ahmad J; Haque A; Alasmary MY; Abdel-Wahab BA; Akhter S
    Expert Rev Vaccines; 2020 Nov; 19(11):1053-1071. PubMed ID: 33315512
    [No Abstract]   [Full Text] [Related]  

  • 13. Nanovaccine-based strategies for lymph node targeted delivery and imaging in tumor immunotherapy.
    He A; Li X; Dai Z; Li Q; Zhang Y; Ding M; Wen ZF; Mou Y; Dong H
    J Nanobiotechnology; 2023 Jul; 21(1):236. PubMed ID: 37482608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymph node-targeted neoantigen nanovaccines potentiate anti-tumor immune responses of post-surgical melanoma.
    Chu Y; Qian L; Ke Y; Feng X; Chen X; Liu F; Yu L; Zhang L; Tao Y; Xu R; Wei J; Liu B; Liu Q
    J Nanobiotechnology; 2022 Apr; 20(1):190. PubMed ID: 35418151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent progress in cancer vaccines and nanovaccines.
    Poudel K; Vithiananthan T; Kim JO; Tsao H
    Biomaterials; 2025 Mar; 314():122856. PubMed ID: 39366184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine-like nanomedicine for cancer immunotherapy.
    Yi Y; Yu M; Li W; Zhu D; Mei L; Ou M
    J Control Release; 2023 Mar; 355():760-778. PubMed ID: 36822241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CpG-Based Nanovaccines for Cancer Immunotherapy.
    Chen W; Jiang M; Yu W; Xu Z; Liu X; Jia Q; Guan X; Zhang W
    Int J Nanomedicine; 2021; 16():5281-5299. PubMed ID: 34385817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Advances of Emerging Spleen-Targeting Nanovaccines for Immunotherapy.
    He X; Wang J; Tang Y; Chiang ST; Han T; Chen Q; Qian C; Shen X; Li R; Ai X
    Adv Healthc Mater; 2023 Sep; 12(23):e2300351. PubMed ID: 37289567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving Cancer Vaccine Efficiency by Nanomedicine.
    Cai J; Wang H; Wang D; Li Y
    Adv Biosyst; 2019 Mar; 3(3):e1800287. PubMed ID: 32627400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions.
    Li Y; Li S; Jiang Z; Tan K; Meng Y; Zhang D; Ma X
    J Nanobiotechnology; 2023 Jul; 21(1):212. PubMed ID: 37415161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.